Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 313
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00040144 | Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B | ||
| NCT04573309 | Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 | ||
| NCT07024563 | Study of Ravulizumab in Pediatric Participants With Primary IgAN | ||
| NCT06160414 | A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants | ||
| NCT04980248 | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) | ||
| NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | ||
| NCT05389449 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | ||
| NCT03310021 | A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects | ||
| NCT01275287 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab | ||
| NCT02531867 | Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan | ||
| NCT00122304 | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab | ||
| NCT01327573 | Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation | ||
| NCT01757431 | The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT04725812 | Complement Regulation to Undo Systemic Harm in Preeclampsia | ||
| NCT03329365 | Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS | ||
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | ||
| NCT01716728 | Identification of Undiagnosed Lysosomal Acid Lipase Deficiency | ||
| NCT00844545 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS | ||
| NCT00751231 | A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI | ||
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency | ||
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | ||
| NCT01522183 | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry | ||
| NCT05578846 | Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics | ||
| NCT05202145 | Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants | ||
| NCT01194804 | E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients | ||
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | ||
| NCT06724809 | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | ||
| NCT04564339 | Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | ||
| NCT03555539 | Study of Danicopan in Participants With Hepatic Impairment | ||
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ||
| NCT02618512 | A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||
| NCT05966467 | Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies | ||
| NCT06079372 | Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa | ||
| NCT04709081 | A Drug Interaction Study of ACH-0145228 | ||
| NCT04956276 | Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia | ||
| NCT02113891 | Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation | ||
| NCT01633489 | Lysosomal Acid Lipase (LAL) Deficiency Registry | ||
| NCT04526210 | Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants | ||
| NCT00838513 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT04202341 | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | ||
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT07157787 | Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | ||
| NCT05234567 | A Prospective Sub-Study of the Global Hypophosphatasia Registry | ||
| NCT02372513 | National Lysosomal Acid Lipase Deficiency Study | ||
| NCT00984113 | Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment | ||
| NCT05047484 | A Study of Multiple Doses of ALXN2050 in Healthy Adults | ||
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | ||
| NCT07352423 | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants | ||
| NCT07413679 | Long-term Safety of Danicopan: IPIG Registry-based Cohort Study | ||
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease |
